Starpharma Holdings Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SPHRY research report →
About the company
Starpharma Holdings Limited is an Australian biopharmaceutical company dedicated to advancing and marketing its proprietary dendrimer technology across global pharmaceutical, life-science, and other sectors. Among its current offerings are VivaGel, a non-antibiotic treatment designed for the management and prevention of bacterial vaginosis, alongside the antiviral VivaGel condom and VIRALEZE antiviral nasal spray. Furthermore, the company's extensive pipeline heavily features its DEP dendrimer drug delivery system, which includes several oncology candidates such as DEP docetaxel, DEP cabazitaxel, and DEP irinotecan, all currently undergoing Phase II clinical trials for various cancers.
- CEO
- Cheryl Maley
- IPO
- 2007
- Employees
- 40
- HQ
- Abbotsford, VIC, AU
Price Chart
- Market Cap
- $199.94M
- P/E
- -95.45
- P/S
- 21.70
- P/B
- 14.33
- EV/EBITDA
- -36.48
- Div Yield
- 0.00%
- Gross Margin
- 60.11%
- Op Margin
- -100.14%
- Net Margin
- -22.67%
- ROE
- -15.96%
- ROIC
- -11.57%
- Revenue
- $5.85M · -29.42%
- Net Income
- $-9,990,000 · -22.35%
- EPS
- $-0.24 · -19.50%
- Op Income
- $-22,070,000
- FCF YoY
- 3.75%
- 52W High
- $5.70
- 52W Low
- $0.60
- 50D MA
- $4.91
- 200D MA
- $3.21
- Beta
- 0.77
- Avg Volume
- 995
Get TickerSpark's AI analysis on SPHRY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our SPHRY coverage
Recent articles, reports, and earnings notes.
No research on SPHRY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SPHRY report →Similar companies
Peers in the same neighborhood.